Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq
January 31, 2020
- Sumitomo Dainippon Starts Japan PI for AI-Designed Drug Candidate
January 31, 2020
- Evrenzo Filed for Anemia in Non-Dialysis CKD Patients in Japan: Astellas/FibroGen
January 31, 2020
- AstraZeneca Taps AI Chatbot to Answer Inquiries from Patient, Healthcare Providers
January 31, 2020
- Takeda Submits Cabozantinib in Japan for HCC, RCC OK Expected Soon
January 30, 2020
- Eisai Pairs Up with US Biotech on Liquid Biopsy-Based Genomic Profiling
January 30, 2020
- Novo’s Hemophilia A Med Esperoct Hits Shelves in Japan
January 30, 2020
- Chugai, UK Institutes Reach Settlement over Actemra Royalty Row
January 29, 2020
- Daiichi Sankyo’s DS-8201 Hits Primary Target in PII Gastric Cancer Trial
January 28, 2020
- KM Biologics Teams Up with JB for Marketing of Globulin Product
January 28, 2020
- Otsuka’s Anti-CGRP Antibody Fremanezumab Smashes Primary Goals in Japan PII/III Studies for Migraine Prevention
January 28, 2020
- Xofluza Holds Top Spot in GP Promotion Ranking in December: Impact Track
January 27, 2020
- Opdivo Misses OS Goal in Platinum-Resistant Ovarian Cancer in PIII: Ono
January 27, 2020
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Takeda to Liquidate Shire’s Irish Holding Firm
January 23, 2020
- Kissei’s Spinocerebellar Degeneration Drug Fails to Meet Primary Goal in PIII, but Shows Positive Results in Severe Patients
January 23, 2020
- Otsuka Ties Up with UK’s PhoreMost, Initial Focus on Gene Therapy
January 22, 2020
- Towa to Develop Adherence Support Tools with Game Maker, Eyes Launch in FY2021
January 22, 2020
- Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
January 21, 2020
- GSK, NCC Join Hands to Propel Cancer Drug Development, Translational Research
January 21, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…